# Inhibitors



## Senaparib

Cat. No.: HY-137450 CAS No.: 1401682-78-7 Molecular Formula:  $C_{24}H_{20}F_{2}N_{6}O_{3}$ Molecular Weight: 478.45 Target: PARP

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Powder

-20°C 3 years 2 years

In solvent -80°C 2 years

> -20°C 1 year

**Product** Data Sheet

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 83.33 mg/mL (174.17 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.0901 mL	10.4504 mL	20.9008 mL
	5 mM	0.4180 mL	2.0901 mL	4.1802 mL
	10 mM	0.2090 mL	1.0450 mL	2.0901 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.35 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.35 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description	Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models <sup>[1]</sup> .
In Vitro	Senaparib (IMP4297) is under the study for advanced PCa, breast cancer and pancreatic cancer <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

1]. P. de Souza, et al. 574P Updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours. ABSTRACT ONLY  VOLUME 31, SUPPLEMENT 4, S490, SEPTEMBER 01, 2020.						
			dical applications. For research use onl			
	Tel: 609-228-6898	Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.com	m		
	Address. 1	Deel Falk DI, Suite Q, Mollillo	utii Juliction, NJ 00032, USA			

Page 2 of 2 www.MedChemExpress.com